IMPORTANT UPDATE (October 2018): SBIR Direct-to-Phase II has been reinstated. Funding Opportunity Announcements PA-18-573 (SBIR, Clinical trial required) and PA-18-574 (SBIR, Clinical trial not allowed).
SBIR Direct-to-Phase II application are 'New' submissions and are not Renewals. Official notice is available here: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-019.html
The SBIR & STTR Omnibus Solicitations are intended to support small business innovation research across a broad spectrum of topic areas. U.S. small businesses that have the research capabilities and technological expertise to contribute to the research and development missions of the awarding components identified in the Omnibus Solicitation are encouraged to submit investigator-initiated SBIR & STTR grant applications in response to the identified topics. Applicants may also consider other areas of research within the mission of any of the awarding components and submit an SBIR & STTR application.
Small business concerns that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds and/or private equity firms CONTINUE TO BE ELIGIBLE to apply to the CDC and NIH SBIR program and compete for up to 15% and 25% respectively of each agency's SBIR set-aside.
In 2018, HHS has issued 4 new funding opportunity announcements (FOAs) for SBIR/STTR omnibus solicitations with FORMS-E and clinical trials policy update. Please check Guide Notice NOT-OD-18-123 for more information.
Visit the NIH SBIR|STTR Funding webpage for information about past SBIR & STTR Omnibus Solicitations.